ReviewFrontiers in pharmacology2019
Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents.
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 98 citations in OpenAlex.
- The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis-A Double-Blind Placebo-Controlled Trial.Nutrients · 2023Trial
- Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.Scientific reports · 2023Trial
- Efficacy and Safety of Sea Salt-Derived Physiological Saline Nasal Spray as Add-On Therapy in Patients with Acute Upper Respiratory Infection: A Multicenter Retrospective Cohort Study.Medical science monitor : international medical journal of experimental and clinical research · 2021Trial
- Development and evaluation of Sargassum polysaccharides-algal oil nanoemulsion for intranasal treatment of allergic rhinitis.Bioresources and bioprocessing · 2026Article
- Comparative Effects of Anti-Inflammatory Therapies on Olfactory Bulb Histopathology and Olfactory Function in a Rat Model of Experimental Allergic Rhinitis.Journal of inflammation research · 2026Article
- Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1.Frontiers in immunology · 2026Article
- A Comprehensive Analysis of the Therapeutic Potential of N-substituted Phenothiazine Derivatives in Medicinal Chemistry.Mini reviews in medicinal chemistry · 2026Review
- Study of the mechanism of methyltransferase 3 regulation of ferroptosis in allergic rhinitis and promotion of allergic rhinitis in an m6A-dependent mechanism.Journal of inflammation (London, England) · 2025Article
- MetaLigand provides a prior-knowledge-guided framework for predicting non-peptide ligand mediated cell-cell communication.Cell reports methods · 2025Article
- Article
- The Roles of Acetylcholine and Muscarinic Receptors in Allergic Rhinitis: Mechanisms, Clinical Insights and Future Directions.Current allergy and asthma reports · 2025Review
- Review
- The role of mast cells in allergic rhinitis.PeerJ · 2025Review
- Screening and transcriptomic analysis of anti-Frontiers in microbiology · 2025Article
- Modulating nasal barrier function and tissue remodeling in inflammatory diseases: the role of ginseng and its bioactive compounds.Tissue barriers · 2025Review
- Astaxanthin ameliorates allergic rhinitisCentral-European journal of immunology · 2025Article
- Mast Cells in Allergic and Non-Allergic Upper Airways Diseases: Sentinel in the Watchtower.International journal of molecular sciences · 2024Review
- Review
- Pathogenesis, Diagnosis, and Treatment of Infectious Rhinosinusitis.Microorganisms · 2024Review
- Development ofPharmaceutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis (AR) is a chronic upper respiratory disease estimated to affect between 10 and 40% of the worldwide population. The mechanisms underlying AR are highly complex and involve multiple immune cells, mediators, and cytokines. As such, the development of a single drug to treat allergic inflammation and/or symptoms is confounded by the complexity of the disease pathophysiology. Complete avoidance of allergens that trigger AR symptoms is not possible and without a cure, the available therapeutic options are typically focused on achieving symptomatic relief. Topical therapies offer many advantages over oral therapies, such as delivering greater concentrations of drugs to the receptor sites at the source of the allergic inflammation and the reduced risk of systemic side effects. This review describes the complex pathophysiology of AR and identifies the mechanism(s) of action of topical treatments including antihistamines, steroids, anticholinergics, decongestants and chromones in relation to AR pathophysiology. Following the literature review a discussion on the future therapeutic strategies for AR treatment is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.